Davunetide

ADNP is essential for brain development and function, and davunetide represents the neuroprotective fragment of that protein, a reductionist attempt to capture ADNP's microtubule- and tau-related activity in a small, brain-penetrant molecule ^[2]. Mechanistic work shows the peptide rapidly distributes to both cytoplasm and nucleus, enhances microtubule content, and corrects nuclear-cytoplasmic abnormalities in ADNP-mutated cells through a microtubule-linked mechanism ^[4].

Clinically, davunetide advanced furthest in PSP, a pure tauopathy. In a randomized, double-blind, placebo-controlled phase 2/3 trial of 313 patients receiving 30 mg intranasally twice daily for 52 weeks, davunetide did not differ from placebo on the PSP Rating Scale or activities-of-daily-living measures, and nasal adverse events were more common; it was concluded not to be an effective treatment for PSP ^[1]. Earlier reports had described cognitive protection in amnestic mild cognitive impairment and enhanced daily function in schizophrenia, supporting continued interest despite the PSP result ^[3].

Davunetide continues to be studied for ADNP syndrome and other tauopathies, and reviews highlight its favorable intranasal bioavailability, safety in trials, and links between ADNP pathways and circadian regulation ^[2]. It remains investigational and is supplied for research use only.

Across the human trials davunetide was generally safe and well tolerated. Intranasal dosing mostly produced local, mild effects such as nasal discomfort, rhinorrhea, and headache, with no clear treatment-related serious safety signal reported in the larger studies. It has been given intranasally and intravenously (as AL-208) in several hundred people combined. The main caveat is not toxicity but the absence of demonstrated benefit, plus the usual gaps for a discontinued peptide: no long-term human safety data beyond about a year, no data in pregnancy, and no modern pharmacovigilance because it never reached market. Anyone treating research-grade material as a supplement is outside any studied context.

The NAP peptide was identified in the lab of Illana Gozes at Tel Aviv University as the shortest active neuroprotective fragment of ADNP. It was developed clinically by Allon Therapeutics of Vancouver under the codes AL-108 (intranasal) and AL-208 (intravenous), branded davunetide. Early work targeted Alzheimer's-type memory loss and post-surgical cognitive impairment; a mild cognitive impairment study and a schizophrenia-cognition study both failed their primary endpoints.

The program then concentrated on progressive supranuclear palsy, a pure tauopathy seen as a cleaner test of a tau-directed drug. That randomized, double-blind, placebo-controlled phase 2/3 trial (published in The Lancet Neurology in 2014) enrolled 313 patients on 30 mg intranasally twice daily for 52 weeks and found no effect. Allon became insolvent in 2013 and its assets were acquired by Paladin Labs; davunetide was effectively shelved. Later reanalyses (for example a 2024 report suggesting a sex-dependent memory signal in prodromal Alzheimer's) have kept modest academic interest alive.

In the tau and microtubule research community davunetide is respected as a well-studied probe and a cautionary tale. Gozes's group continues to publish on its mechanism and on ADNP biology, so it remains a useful reference peptide for microtubule and tau work. Among practitioners and clinicians it is mostly remembered for the high-profile PSP failure, which is often cited when discussing how strong preclinical tau data can still fail in the clinic. In the research-chemical and peptide-hobbyist world it gets occasional attention as a nasal nootropic, but there is no human efficacy evidence to support that use, and honest sources say so.